Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis

Blood

Volumn 120, Issue 16, 2012, Pages 3336-3344

  Laitala, Anu ^a   Aro, Ellinoora ^a   Walkinshaw, Gail ^b   Mäki, Joni M ^a   Rossi, Maarit ^a   Heikkilä, Minna ^a   Savolainen, Eeva Riitta ^c   Arend, Michael ^b   Kivirikko, Kari I ^a   Koivunen, Peppi ^a   Myllyharju, Johanna ^a  

^a UNIVERSITY OF OULU   (Finland)

^b FIBROGEN INC   (United States)

^c OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OXYGENASE; PROLY 4 HYDROXYLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

EID: 84868104099     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-441824     Document Type: Article

References (50)

1. Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood. 2009;114(10):2015-2019.
2. Yoon D, Ponka P, Prchal JT. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol. 2011;300(6):C1215-1222.
3. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402. (Pubitemid 351681994)
4. Fraisl P, Aragonés J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov. 2009;8(2):139-152.
5. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468. (Pubitemid 32335941)
6. Jaakkola P, Mole DR, Tian Y-M, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468-472. (Pubitemid 32335942)
7. Yu F, White SB, Zhao Q, Lee FS. HIF-alpha is regulated by stimulus sensitive proline hydroxylation. Proc Natl Acad Sci U S A. 2001;98(17):9630- 9635. (Pubitemid 32769354)
8. Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol. 2010;299(1):F1-F13.
9. Hintze KJ, McClung JP. Hepcidin: A critical regulator of iron metabolism during hypoxia. Adv Hematol. 2011;2011:510304.
10. Mastrogiannaki M, Matak P, Mathieu JR, et al. Hepatic HIF-2 down-regulates hepcidin expression in mice through EPO-mediated increase in erythropoiesis. Haematologica. 2012;97(6):827-834.
11. Bruick RK, McKnight SL. A conserved family of prolyl 4-hydroxylases that modify HIF. Science. 2001;294(5545):1337-1340. (Pubitemid 33063099)
12. Epstein ACR, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1):43-54. (Pubitemid 32972036)
13. Ivan M, Haberberger T, Gervasi DC, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A. 2002;99(21):13459-13464. (Pubitemid 35215403)
14. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxiainducible transcription factors. Biochem Biophys Res Commun. 2002;296(2):343-349.
15. Koivunen P, Tiainen P, Hyvärinen J, et al. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. J Biol Chem. 2007;282(42):30544-30552. (Pubitemid 350035186)
16. Myllyharju J. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Ann Med. 2008;40(6):402-417.
17. Takeda K, Ho VC, Takeda H, Duan L-J, Nagy A, Fong G-H. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006;26(22):8336-8346. (Pubitemid 44748568)
18. Takeda K, Cowan A, Fong G-H. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 2007;116(7):774-781. (Pubitemid 47255995)
19. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood. 2009;111(6):3229-3235.
20. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG Jr. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2008;111(6):3236-3244.
21. Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010;329(5990):407.
22. Hyvärinen J, Hassinen IE, Sormunen R, et al. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem. 2010;285(18):13646- 13657.
23. Hyvärinen J, Parikka M, Sormunen R, et al. Deficiency of a transmembrane prolyl 4-hydroxylase in zebrafish leads to basement membrane defects and compromised kidney function. J Biol Chem. 2010;285(53):42023-42032.
24. Myllyharju J. HIF prolyl 4-hydroxylases and their potential as drug targets. Curr Pharm Des. 2009;15(33):3878-3885.
25. Muchnik E, Kaplan J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs. 2011;20(5):645-656.
26. Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007;110(6):2140-2147. (Pubitemid 47443933)
27. Rosenberger C, Rosen S, Shina A, et al. Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol Dial Transplant. 2008;23(11):3472-3478.
28. Robinson A, Keely S, Karhausen J, et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology. 2008;134(1):145-155. (Pubitemid 350309309)
29. Schneider C, Krischke G, Keller S, et al. Shortterm effects of pharmacologic HIF stabilization on vasoactive and cytotrophic factors in developing mouse brain. Brain Res. 2009;1280(1):43-51.
30. Milosevic J, Adler I, Manaenko A, et al. Nonhypoxic stabilization of hypoxia-inducible factor alpha (HIF-alpha): relevance in neural progenitor stem cells. Neurotox Res. 2009;15(4):367-380.
31. Bernhardt WM, Gottmann U, Doyon F, et al. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci U S A. 2009;106(50):21276-21281.
32. Paliege A, Rosenberger C, Bondke A, et al. Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int. 2010;77(4):312-318.
33. Langsetmo I, Nichols B, Seeley T, et al. FG-2216 corrects anemia and improves iron utilization in a rat model of anemia of chronic disease: comparison to darbepoetin [abstract]. J Am Soc Nephrol. 2005;16:481A. Abstract F-PO674.
34. Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003;278(33):30772-30780. (Pubitemid 36994584)
35. Hirsilä M, Koivunen P, Xu L, Seeley T, Kivirikko KI, Myllyharju J. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J. 2005;19(10):1308-1310. (Pubitemid 41113732)
36. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A. 2006;103(3):654-659. (Pubitemid 43153081)
37. Ladroue C, Hoogewijs D, Gad S, et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica. 2012;97(1):9-14.
38. Albiero E, Ruggeri M, Fortuna S, et al. Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica. 2012;97(1):123-127.
39. Rankin EB, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63-74.
40. Weidemann A, Kerdiles YM, Knaup KX, et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest. 2009;119(11):3373-3383.
41. Besarab A, Hulter HN, Klaus S, et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract]. J Am Soc Nephrol. 2010;21(201):95A. Abstract SA-FC416.
42. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12):2151-2156.
43. Provenzano R, Goodkin D, Klaus S, et al. Evaluation of FG-4592, a novel oral hypoxiainducible factor prolyl hydroxylase inhibitor, to treat anemia in hemodialysis patients [abstract]. Am J Kidney Dis. 2011;57(4):B80. Abstract 253.
44. Barrett TD, Palomino HL, Brondstetter TI, et al. Pharmacological characterization of 1-(5chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)- 1Hpyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor. Mol Pharmacol. 2011;79(6):910-920.
45. Köditz J, Nesper J, Stiehl DP, et al. Oxygendependent ATF stability is mediated by the PHD3 oxygen sensor. Blood. 2007;110(10):3610-3617. (Pubitemid 350159628)
46. Xie L, Xiao K, Whalen EJ, et al. Oxygen-regulated beta2-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal. 2009;2(78):ra33.
47. Zhang Q, Gu J, Li L, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009;16(5):413-424.
48. Luo W, Hu H, Chang R, et al. Pyryvate kinase M2 is a PHD3-stimulated coactivator for hypoxiainducible factor 1. Cell. 2011;145(5):732-744.
49. Aragonés J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008;40(2):170-180. (Pubitemid 351171394)
50. Bishop T, Gallagher D, Pascual A, et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/-mice. Mol Cell Biol. 2008;28(10):3386-3400. (Pubitemid 351657101)